Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases — Stella

Home/NSCLC Stage IV/

View on ClinicalTrials.gov

Recruiting

Back to NSCLC Stage IV trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

Netherlands

NKI-AvL, Amsterdam

University Medical Center Groningen, Groningen

Maastricht University Medical Center, Maastricht

Key details

Phase

Safety & dosing

Sponsor

Maastricht University Medical Center

Collaborators

Gilead Sciences

Enrollment target

~25 participants

Started

April 2025

Primary completion

November 2026

Age range

18 Years and older

Last updated May 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.